# US 6,787,637 B1 · N-Terminal amyloid-β antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,787,637 B1
- Document ID: US6787637B1
- Status: Granted
- Kind: B1
- Application number: 09/724,551
- Filed: 2000-11-28
- Granted: 2004-09-07
- Earliest claimed: 1999-05-28
- Assignees: Neuralab Limited
- Inventors: Dale B. Schenk
- Web page: https://patentgrep.com/patent/US6787637B1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 39/0007: {Nervous system antigens; Prions}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C07K 14/4711: {Alzheimer's disease; Amyloid plaque core protein}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/505: {comprising antibodies}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/55572: {Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/77: Internalization into the cell
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred including N-terminal fragments of Aβ and antibodies binding to the same.

## Claims

### Claim 1

A pharmaceutical composition comprising an antibody that specifically binds to an epitope within residues 1-7 of Aβ and a pharmaceutical carrier, wherein the isotype of said antibody is human IgG1.

### Claim 2 (depends on 1)

The pharmaceutical composition according claim 1, wherein said antibody specifically binds to an epitope within residues 1-4 of Aβ.

### Claim 3 (depends on 1)

The pharmaceutical composition according claim 1, wherein said antibody specifically binds to an epitope within residues 1-3 of Aβ.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the antibody specifically binds to an epitope within residues 3-7 of Aβ.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, which is a sustained release composition.

### Claim 6

A pharmaceutical composition comprising a chimeric or humanized antibody that specifically binds to an epitope within residues 1-7 of Aβ and a pharmaceutical carrier.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, which is a sustained release composition.
